Tag: Pablo J. Cagnoni
Rubius to lay off about 70 R.I. employees, considering sale of...
SMITHFIELD – Rubius Therapeutics plans to lay off 75% of its workforce, including about 70 of its 101 employees in Rhode Island, and is...
Rubius Therapeutics logs $50.2M loss in Q2
CAMBRIDGE, Mass. – The clinical-stage biopharmaceutical company Rubius Therapeutics Inc. reported a loss of $50.2 million in the second quarter, or 56 cents per...
Rubius Therapeutics reports $40.9M loss in Q3
CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a loss of $40.9 million, or 51 cents per diluted share, in the third quarter.
The clinical-stage biopharmaceutical...
Rubius Therapeutics reports $163.5M loss in 2019; focuses on oncology and...
PROVIDENCE – Rubius Therapeutics Inc. reported a year-end loss of $163.5 million in 2019, an increase from $89.2 million in 2018.
Loss per diluted share...
Rubius reports $39.4M loss in Q2, heralds progress
PROVIDENCE – Rubius Therapeutics Inc. reported on Tuesday a loss of $39.4 million in the second quarter of 2019, or 50 cents per diluted...
Rubius Therapeutics reports $32.6M loss in Q1
SMITHFIELD – Rubius Therapeutics Inc. reported a net loss of $32.6 million in the first quarter of 2019, or 42 cents per diluted share,...
Rubius reports $26.4M loss for Q3
PROVIDENCE – Cambridge, Mass.-headquartered Rubius Therapeutics Inc. announced a $26.4 million net loss for the third quarter of 2018 Tuesday. The company reported an...
Rubius Therapeutics enters agreement to buy former Alexion site in Smithfield
SMITHFIELD – Rubius Therapeutics Inc., the Cambridge, Mass.-based company recently approved by the R.I. Commerce Corp. for up to $9 million in incentives to...
- Featured Event -
